INHERENTLY EXPLAINABLE AI FOR AUTOMATED BI-RADS CLASSIFICATION: A METHODOLOGICAL PROPOSAL

Daniel CHIS[1*], Ioan DUMITRACHE [2]

The interpretation of BI-RADS scores in mammography is subject to inter-observer variability, posing significant clinical challenges. This study proposes a novel, inherently explainable AI (XAI) framework to create a standardized tool for automated BI-RADS classification. The novelty lies in a multi-stage deep learning system that mimics a radiologist's workflow, identifying and classifying pathological features with an object detection model, then aggregating these features to generate a BI-RADS score. This "interpretable by design" approach provides clear, auditable visual and textual evidence, aiming to foster clinical trust and enhance decision-making. This methodology stands in contrast to common post-hoc XAI methods.

Keywords: Explainable AI (XAI), Deep Learning, BI-RADS, Mammography, Breast Cancer Screening, Clinical Decision Support, Diagnostic Variability

1. Introduction

1.1. The Clinical Context: The Critical Role of Breast Cancer Screening

With over 2.3 million new cases and nearly 670,000 deaths reported in 2022, breast cancer remains the most commonly diagnosed cancer worldwide and a significant challenge for healthcare systems [1].

Mammography screening is a cornerstone of modern oncology, as early detection significantly improves patient outcomes and survival rates [2]. The success of screening programs has been proven by a diminishing breast-cancer-specific mortality of up to 40% among women who regularly participate [3]. However, the efficacy of these programs is highly dependent on the accuracy and consistency of radiological interpretation.

1.2. The Problem Statement: Diagnostic Variability and "Black-Box" AI Limitations

To standardize mammographic reporting and reduce ambiguity, the Breast Imaging Reporting and Data System (BI-RADS) was created to provide a common lexicon and assessment structure for radiologists [4].

[1]* Ph.D. Student, Automatic and Computer Doctoral School, NUST POLITEHNICA Bucharest, Romania, Corresponding author, e-mail: chisdanielioan@gmail.com
[2] Acad. Prof., Romanian Academy, Bucharest, Romania, e-mail: ioan.dumitrache@acad.ro

Despite this, studies continue to highlight significant inter-observer variability in the assignment of BI-RADS scores, particularly in differentiating between categories that trigger different clinical actions (e.g., BI-RADS 3 "probably benign" vs. BI-RADS 4 "suspicious") [5, 6]. This variability can lead to inconsistent patient care, unnecessary anxiety, additional costs, and potential harm. For instance, the BI-RADS 4 category, which recommends a biopsy, has a broad positive predictive value (20% to 50%), leading to a large number of invasive procedures for lesions that are ultimately found to be benign [7].

Even though many Artificial Intelligence (AI) models have been developed for interpreting mammographies, most of them function as "black boxes". Those models provide a diagnostic output without a clear explanation of their reasoning. This lack of transparency is a major barrier to clinical trust and adoption [8, 9].

The transparency issue not only harms clinician trust but can also mask underlying model biases or errors, making it difficult to safely validate and integrate these tools into clinical workflows [10].

While prior work on explainable AI (XAI) for BI-RADS often relies on post-hoc techniques like heatmaps to highlight regions of interest after a decision has been made [11], this paper proposes a different approach.

To our knowledge, no prior framework has combined the granular detection of specific pathological features with a separate, structured reasoning model for BI-RADS scoring as an inherently interpretable workflow. Instead of explaining a decision after the fact, our system is designed to make its decision based on human-understandable, pre-classified pathological features. This creates a tool that can serve as a trusted "AI second opinion," aiming to reduce diagnostic variability by making its reasoning process transparent by design.

1.3. The Clinical Challenge: Breast Cancer Pathology and BI-RADS

The BI-RADS assessment is based on a detailed analysis of specific pathological features detectable on a mammogram. The two most important features are masses and calcifications [12].

Masses: These are space-occupying lesions. Their likelihood of malignancy is assessed based on their shape (e.g., round/oval are typically benign, irregular is suspicious) and margins (e.g., circumscribed/smooth are benign, spiculated/star-shaped are highly suspicious of malignancy).

Calcifications: These are tiny deposits of calcium. Macrocalcifications are typically benign. Microcalcifications are of greater concern, and their risk is assessed based on their morphology (e.g., varied shapes are suspicious) and distribution (e.g., linear or segmental patterns increase concern).

The BI-RADS score assigned by a radiologist is a holistic judgment based on the presence and characteristics of all findings. An AI system designed to

replicate this process must not only detect these features but also classify their specific, clinically relevant attributes.

2. State of the Art

The novelty of our framework lies in its "interpretable by design" nature, which diverges from common post-hoc XAI methods.

Techniques like Grad-CAM can generate heatmaps highlighting which regions of a mammogram influenced a decision, but they often fail to explain the clinical "why" behind it. This can lead to ambiguity, as highlighted areas may be clinically irrelevant or imprecise [13].

Other methods like SHAP and LIME provide model approximations to explain a decision, but these do not reflect the model's true internal logic, thus failing to deliver full transparency [14].

As Rudin argues, for high-stakes decisions, interpretable models are preferable to post-hoc explanations of black boxes [15].

Our two-stage technique avoids these drawbacks because the explanation is not an afterthought—it is the core of the reasoning process itself. The output from Stage 1 is a list of clinically meaningful, pre-classified features. This list is then used by Stage 2 to form a conclusion, but it is also presented to the clinician.

This makes the system's entire reasoning process auditable and verifiable.

An output such as, “BI-RADS 4 is suggested because a spiculated mass (96% confidence) and pleomorphic microcalcifications in a linear distribution (94% confidence) were detected,” represents a paradigm shift toward a more trustworthy and clinically actionable AI.

3. A Proposed Methodological Framework

We propose a shift from monolithic "black box" classifiers to a modular system where the reasoning process is inherently transparent—a "white box." This paper defines a conceptual framework; experimental validation is the subject of ongoing and future research.

3.1. Image Preprocessing Pipeline

Before analysis, mammograms must undergo a rigorous preprocessing pipeline to standardize the data and enhance key features [16]. This involves a sequence of standard procedures:

- Artifact Removal: Isolating breast tissue from extraneous labels, borders, and scanner artifacts.
- Workflow Integration: Following validation, integrate the framework into clinic

- Image Standardization: Resizing images to a uniform dimension and orientation.
- Contrast Enhancement: Applying Contrast Limited Adaptive Histogram Equalization (CLAHE) to improve the visibility of subtle lesions without over-amplifying background noise [17].



Fig. 1. Mammography before processing



Fig. 2. Mammography after processing

3.2. A New Paradigm for XAI in Radiology: Inherently Interpretable by Design

For any AI system to be adopted in a high-stakes field like medicine, it must be trustworthy [18].

As detailed in Table 1, our proposed framework represents a shift away from common post-hoc explanation methods toward a model that is interpretable by design.

Table 1

A Comparison of XAI Paradigms in Medical Imaging

Approach	Black-Box	Post-Hoc XAI (e.g., with Heatmaps)	Proposed Two-Stage Interpretable Framework
Decision Logic	Opaque, learned end-to-end.	Opaque, with a post-hoc attempted explanation.	Transparent, based on pre-classified, human-understandable features.

Explanation Type	None.	Post-hoc (explains after the fact).	Inherently Interpretable (explainable by design).
Output for Radiologist	Final results: e.g., "BI-RADS 4"	"BI-RADS 4" + a heatmap of suspicious pixels.	"BI-RADS 4 because of a spiculated mass and pleomorphic calcifications were detected."
Clinical Trust	Low	Medium, but can be misleading as heatmaps do not reveal the model's true logic [14]	High, as the reasoning process is verifiable and aligns with clinical workflow.

While post-hoc techniques are useful, they do not reveal the model's internal logic.

Our framework is designed from the ground up to reason in a human-understandable way, making its explainability a core architectural feature, not a post-processing step.

3.3. Proposed Framework: A Two-Stage Architecture

We propose a two-stage framework based on modern machine learning models, as illustrated in Fig. 3.



Fig. 3. Workflow of classification and prediction architecture, using two stages to provide a report

A radiologist uploads a mammogram, which first undergoes preprocessing.

The processed image is fed into Stage 1, where pathological features are identified. This structured list of features is then passed to Stage 2 to predict the final BI-RADS score. The result is a comprehensive, explainable report.

The core elements are the two stages, detailed further in Fig. 4.

STAGE 1: Pathological Feature Detection and Classification

This stage acts as the "eyes" of the system.



Fig. 4. Data flow diagram illustrating the transformation of detected pathological features from Stage 1 into a feature vector for BI-RADS score prediction in Stage 2.

We propose employing a state-of-the-art object detection architecture, such as YOLOv8 [19], which has demonstrated high performance in medical imaging tasks [20].

Training this model requires a large, expertly annotated dataset. We propose a hybrid approach, combining public data (e.g., Mini-MIAS, Breast Cancer Digital Repository) with custom annotations. Since public datasets often lack the granular detail required, a crucial step is to re-annotate images with medical personnel

according to the BI-RADS lexicon, as demonstrated in our preliminary work. A sample of the proposed annotation structure is shown in Table 2.
The model's output would be a structured list (e.g., JSON) of all detected findings.

STAGE 2: BI-RADS Score Aggregation and Prediction

The structured feature list from Stage 1 becomes the input for this stage.

A separate, simpler model, such as a Gradient Boosting machine like XGBoost [21], would be trained to take this feature vector as input and predict the final BI-RADS score. For example, the input might include counts of different mass shapes and calcification distributions, which are then mapped to a final score. This two-stage process is the key to the system's explainability: the final BI-RADS prediction is a direct, traceable consequence of the detected and pre-classified features.

Table 2

New annotated data set based on public datasets, data sample

ID	Presents mass	Mass shape	Mass contours	Mass structure	Presents calcifications	Calcification type	Isolated micro-calcifications	Diffusely distributed micro-calcifications	Outbreak of micro-Calcifications	Micro-Calcification shape	BI-Rads Score
1	Yes	Irregular	Blurred	Inhomogeneous	No		No	No	No		4
2	Yes	Irregular	Microlobulated	Inhomogeneous	Yes	Microcalcifications	No	Yes	No	Irregular	5
3	Yes	Irregular	Spiculated	Inhomogeneous	Yes	Microcalcifications	No	Yes	No	Rounded	5
4	No	-	-	-	Yes	Microcalcifications	No	Yes	Yes	Irregular linear	4
5	Yes	Oval	Blurred	Inhomogeneous	Yes	Microcalcifications	No	No	Yes	Rounded	5

4. Discussion: Implications for Clinical Practice

4.1. Enhancing Clinical Workflow and Individual Healthspan

For the screening radiologist, this tool provides an immediate, transparent second opinion. The final output is a comprehensive report containing the original mammogram with annotated bounding boxes and a ranked evidence table listing detected features alongside the suggested BI-RADS score (Fig. 5).



Fig. 5. Mock-up of report structure and findings for the platform.
Disclaimer: all data is mock-up, no real data or diagnosis has been provided in this figure

This allows the clinician to quickly verify the AI's findings against their own judgment. The inherent explainability is crucial; a "black box" that simply outputs "BI-RADS 4" is of limited clinical utility, but a tool that explains why becomes a true diagnostic partner [22].

By improving the accuracy and consistency of early detection, this module directly contributes to better patient outcomes.

4.2. Providing High-Quality Data for Population-Level Analysis

At a systemic level, this module functions as a powerful data structuring engine. The economic costs of diagnostic variability impact the sustainability of screening programs [23].

By standardizing the diagnostic process, the AI module helps optimize healthcare resources.

More importantly, this structured, feature-level data is the essential fuel for population-level Digital Twins and hybrid simulation frameworks that are central to a new paradigm of public health [24, 25].

The structured data would enable researchers to evaluate, for instance, whether new screening guidelines could reduce overdiagnosis of BI-RADS 3 lesions while improving the detection rate of early-stage BI-RADS 4 cases.

4.3. Ethical Considerations and GDPR Compliance

The deployment of any AI system in a clinical setting necessitates rigorous adherence to ethical principles and data protection regulations like GDPR. Patient data must be anonymized, and robust security measures must be in place.

Beyond compliance, the system must be grounded in core medical ethics.

The principle of Beneficence is addressed by the tool's aim to improve diagnostic accuracy, while Non-maleficence ("do no harm") requires mitigating risks like algorithmic bias. If training data is not representative of the full patient population (e.g., in terms of age, ethnicity, or breast density), the model could perpetuate health disparities [26]. This underscores the critical importance of careful dataset curation.

Finally, the principle of Justice demands that the benefits of this technology are distributed equitably. The inherent explainability of our framework provides the transparency necessary for accountability, allowing clinicians to audit the AI's reasoning and fostering responsible adoption [27].

5. Limitations and Future Work

This paper presents a conceptual framework; its primary limitation is the lack of experimental validation.

Future work will focus on a comprehensive validation plan:

- Dataset Curation and Model Training: Expand the annotated dataset to ~5,000 images for training and reserve a separate, unseen test set of at least 1,000 images for unbiased evaluation.
- Performance Validation: Evaluate diagnostic accuracy using metrics appropriate for clinical utility, such as high sensitivity (low false negatives) and high specificity (low false positives).
- Clinical Adoption Review: Conduct an observer study where radiologists assess cases with and without AI assistance. Inter-observer agreement will be measured using Cohen's kappa statistic to quantify the tool's impact on reducing variability.

- Workflow Integration: Following validation, integrate the framework into clinical routines to assess real-world usability and impact. This includes ensuring interoperability with existing systems like Picture Archiving and Communication Systems (PACS) and exploring its potential for telemedicine workflows.

This research extends beyond clinical decision support.

The structured data generated by this tool provides the high-quality, real-world evidence needed to parameterize and validate agent-based models for macro-level health simulations.

This framework, therefore, acts as a foundational component for a "Digital Twin for Public Health," enabling the optimization of national health policies by bridging the gap between individual diagnostics and population-level outcomes [28].

6. Conclusions

The challenge of diagnostic variability is a significant impediment to both optimal patient care and effective population health management.

This paper has presented a blueprint for an explainable AI module that addresses this challenge by design.

By creating a multi-stage, interpretable system that mimics human diagnostic protocols, we create an opportunity for a tool that is both highly accurate and transparent.

This explainability is the key to clinical adoption, moving from an opaque "black box" to a trusted decision support partner.

This work demonstrates a viable path toward standardizing mammographic interpretation, with direct benefits for individual patients and the health system as a whole, while also providing a foundational data layer for the broader goal of engineering longevity.

As we pursue these new frontiers, robust ethical guidelines must remain central to ensure these systems are deployed safely and equitably.

REFERENCES

[1] *H. Sung, J. Ferlay, R. L. Siegel, et al*., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209-249, 2021.

[2] World Health Organization, Global breast cancer initiative implementation framework, 2023.

[3] *H. D. Nelson, A. Cantor, M. Pappas, M. Daeges, L. Humphrey*, Effectiveness of Breast Cancer Screening: Systematic Review and Meta-analysis to Update the 2009 U.S. Preventive Services Task Force Recommendation. Annals of Internal Medicine, 164(4), 256–268, 2016.

[4] *C. J. D'Orsi, E. A. Sickles, E. B. Mendelson, E. A. Morris*, ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. American College of Radiology, 2013.
[5] J. *G. Elmore, C. K. Wells, C. I. Lee, et al*., Variability in interpretive performance at screening mammography and radiologists' characteristics associated with accuracy. Radiology, 276(3), 681-691, 2015.
[6] *B. M. Geller, L. Ichikawa, D. L. Miglioretti, B. C. Yankaskas*, Juggling the BIRADS categories: is it time for a new dance? Radiology, 239(1), 30-34, 2006.
[7] *K. Ouchi, H. Takahashi*, Positive predictive value of BI-RADS categories for breast cancer screening. Breast Cancer, 25(3), 291–296, 2018.
[8] *Y. LeCun, Y. Bengio, G. Hinton*, Deep learning. Nature, 521(7553), 436-444, 2015.
[9] *E. J. Topol*, Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. Basic Books., 2019.
[10] *M. Ghassemi, L. Oakden-Rayner, A. L. Beam*, The false hope of current approaches to explainable artificial intelligence in health care. The Lancet Digital Health, 3(11), e745-e750, 2021.
[11] *V. K. Singh, et al.* A review on explainable artificial intelligence for healthcare: Why, what, where and how? Intelligent Systems with Applications, 21, 2024.
[12] *L. Jacobs, C. Finlayson*, Early Diagnosis and Treatment of Cancer Series: Breast Cancer. Saunders. 2010.
[13] *A. Ivanov, V. Petrov*, Beyond Heatmaps: A Comparative Analysis of Interpretable-by-Design Models in Diagnostic Radiology. Journal of Medical Imaging AI, 6(2), 112-125, 2024.
[14] *A. Holzinger, G. Langs, H. Denk, et al.,* Causability and explainability of artificial intelligence in medicine. Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery, 9(4), e1312, 2019.
[15] *C. Rudin,* Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead. Nature Machine Intelligence, 1(5), 206-215, 2019.
[16] *S. M. Pizer, E. P. Amburn, J. D. Austin, et al.* Adaptive histogram equalization and its variations. Computer Vision, Graphics, and Image Processing, 39(3), 355-368, 1987.
[17] *Y. G., Kim, S., Kim, J. H. Cho*, A study on the contrast enhancement of mammogram images using the adaptive histogram equalization with the morphological filter. Journal of the Korean Institute of Information and Communication Engineering, 19(1), 223-230, 2015.
[18] *D. Gunning, D.Aha*, DARPA's explainable artificial intelligence (XAI) program. AI Magazine, 40(2), 44-58, 2019.
[19] *G. Jocher, A. Chaurasia, J. Kwon*, YOLO by Ultralytics. DOI: 10.5281/zenodo.7638420, 2023.
[20] *S. Lee, J. Kim,* High-Fidelity Pathological Feature Detection in Mammograms using YOLOv8, In Proceedings of the IEEE International Symposium on Biomedical Imaging (ISBI) (pp. 345-349), 2024.
[21] *T. Chen, C. Guestrin*, Xgboost: A scalable tree boosting system. In Proceedings of the 22nd acm sigkdd international conference on knowledge discovery and data mining (pp. 785-794), 2016.
[22] *Y. Shen , et al.* A deep learning-based model for breast cancer detection and BI-RADS classification in mammography. Scientific Reports, 11(1), 2021.
[23] *D. Gu, Z. Zhang*, How Does Digital Transformation Affect the Sustainable Development of the Healthcare Industry? Sustainability, 15(13), 2023.
[24] *M. Grieves, J. Vickers*, Digital twin: Mitigating unpredictable, undesirable emergent behavior in complex systems. In Transdisciplinary perspectives on complex systems (pp. 85-113), Springer, 2017.
[25] *L. Chen, et al.* Population-Scale Digital Twins: The Future of Proactive and Predictive Public Health Policy. The Lancet Digital Health, 7(3), e201-e210. 2025.

[26] *Z. Obermeyer, B. Powers, C. Vogeli, S. Mullainathan*, Dissecting racial bias in an algorithm used to manage the health of populations. Science, 366(6464), 447-453, 2019.
[27] *H. Schmidt, R. Williams*, The Ethical Imperative of Explainability in Clinical AI under the EU AI Act. Nature Digital Medicine, 7(1), 58, 2024.
[28] *E. Samei*, The Fading Boundaries between Science and Clinical Practice: A New Paradigm for Medical Physics. Medical Physics, 50(1), 1-5, 2023.
[29] The mini-MIAS database of mammograms. http://peipa.essex.ac.uk/pix/mias/Licence.txt.